uploads/2017/12/Oral-care-1.png

How JNJ’s Consumer Products Performed in 3Q17

By

Updated

Oral care revenue trends

In 3Q17, Johnson & Johnson’s (JNJ) oral care products generated revenues of $382 million, which reflected a 3% decline quarter-over-quarter. JNJ’s oral care year-over-year revenues remained flat. In 3Q17, in the US market and international markets, JNJ’s oral care reported revenues of $154 million and $228 million, respectively, compared to $156 million and $227 million in 3Q16.

JNJ’s oral care products reported YTD September 2017 revenues of $1.14 billion compared to $1.17 billion in the corresponding period of 2016.

Article continues below advertisement

Women’s health revenue trends

In 3Q17, Johnson & Johnson’s women health products generated revenues of $270 million, a 2% decline on a quarter-over-quarter basis. In 3Q17, Women’s health revenues remained flat compared to 3Q16.

In 3Q17, in the US and international markets, JNJ’s women’s health products reported revenues of $3 million and $267 million, respectively. JNJ’s women’s health segment reported YTD September 2017 revenues of $788 million compared to $803 million in the corresponding period in 2016.

Wound care revenue trends

In 3Q17, Johnson & Johnson’s wound care reported revenues of $192 million, a ~17% decline quarter-over-quarter. In 3Q17, wound care revenues remained flat compared to 3Q16.

In 3Q17, in the US and international markets, wound care products generated revenues of $104 million and $88 million, respectively, compared to $111 million and $81 million in 3Q16.

Wound care products generated YTD September 2017 revenues of $599 million compared to $621 million in YTD September 2016.

In 3Q17, Novartis (NVS), Abbott Laboratories (ABT), and Bayer (BAYZF) generated revenues of $12.4 billion, $6.8 billion, and 8 billion euros, respectively, in the consumer products market. The iShares Core S&P 500 ETF (IVV) invests ~1.7% of its total portfolio holdings in Johnson & Johnson.

Advertisement

More From Market Realist